[Teaching of the humanized care: evaluation and trends of the scientific production].

Rev Bras Enferm

Núcleo de Estudos e Pesquisas em Saúde Integral, Departamento de Enfermagem, Universidade Federal de Goiás, Goiânia, GO.

Published: June 2009

From the divulgation of the Curricular Directories of Nursing the degree courses have the mission of to form generalist, critical, reflexive and humanist nurse, what requests efforts of the education institutions in the search of strategies that make possible the development of those abilities. Descriptive study of exploratory of bibliographical nature, had as objective to analyze scientific production in nationals periodic about teaching of the humanized care on the graduation in nursing, among 1990/2008. The occurrence of the production the studied newspapers us allows to affirm that there is a tendency each time bigger about the nurse formation in what he concerns the teaching of the humanized care. In the analysis we identified the Curricular Directories contribution, besides facilitative strategies in the teaching of the humanized care. For the development of that competence it is fundamental emphasis in that dimension in the academic formation and the permanent education.

Download full-text PDF

Source
http://dx.doi.org/10.1590/s0034-71672008000600014DOI Listing

Publication Analysis

Top Keywords

humanized care
16
teaching humanized
12
curricular directories
8
[teaching humanized
4
care
4
care evaluation
4
evaluation trends
4
trends scientific
4
scientific production]
4
production] divulgation
4

Similar Publications

Preclinical Models for Functional Precision Lung Cancer Research.

Cancers (Basel)

December 2024

Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817, USA.

Patient-centered precision oncology strives to deliver individualized cancer care. In lung cancer, preclinical models and technological innovations have become critical in advancing this approach. Preclinical models enable deeper insights into tumor biology and enhance the selection of appropriate systemic therapies across chemotherapy, targeted therapies, immunotherapies, antibody-drug conjugates, and emerging investigational treatments.

View Article and Find Full Text PDF

The Difficulties of Treating Complement-3-Mediated Glomerulopathy.

Am J Ther

January 2025

Northwell, New Hyde Park, NY, Department of Medicine, Manhasset, NY.

Background: C3 glomerulopathy (C3G) is a rare disease affecting the complement alternative pathway, categorized into dense deposit disease and C3 glomerulonephritis. Dense deposit disease predominantly affects younger individuals, while C3 glomerulonephritis tends to manifest in older populations. The diseases are characterized by dysregulation of the complement alternative pathway, leading to the deposition of complement components in the glomeruli and subsequent renal dysfunction.

View Article and Find Full Text PDF

Aim: Toripalimab is the first antitumor programmed cell death protein 1 (PD-1) antibody approved in China. For better patient management, it is important to understand the real-world outcomes of toripalimab in treating patients with lung cancer in the real world outside of clinical trials to improve patient care.

Methods: We retrospectively examined the clinical data of 80 patients with lung cancer who received the PD-1 inhibitor (toripalimab).

View Article and Find Full Text PDF

We present a case of a woman in her 40s with disseminated enterovirus infection in the setting of maintenance therapy with ocrelizumab for relapsing-remitting multiple sclerosis. The patient originally presented with fever, bilateral lower limb swelling and hypoalbuminaemia. She subsequently developed a productive cough and diarrhoea, and a viral respiratory multiplex panel detected rhino/enterovirus.

View Article and Find Full Text PDF

Radiological and Pathological Analysis of Pembrolizumab-Associated Lung Lesions: Diagnostic Challenges and Management.

Am J Case Rep

January 2025

Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Tsu, Mie, Japan.

BACKGROUND Pembrolizumab, a programmed cell-death protein-1 (PD-1)-targeting antibody, extends survival in cancer patients but may cause lung injury as a side effect. This immunotherapy enhances the immune system's ability to recognize and eliminate cancer cells. However, its immunomodulatory action can sometimes lead to immune-related adverse events, including lung injury.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!